Granted Patent
B2
US 12,357,590 · App. 17/371,626 · Granted Jul 15, 2025
Binge behavior regulators
Assignee:
CLEARMIND MEDICINE INC.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Methods and compositions utilizing 2-aminoindan derivatives collectively represented by Formula I as described and defined in the specification for regulating binge behavior, particularly binge drinking, are disclosed.
Claims (18)
1. A method of regulating binge behavior, the method comprising administrating to a subject in need thereof a pharmaceutically acceptable salt of a compound:
selected from:
5-methoxy-2-aminoindan;
5,6-dimethoxy-2-aminoindan;
5-methoxy-2-(N-propylamino) indan; and
5,6-dimethoxy-2-(N-propylamino) indan.
2. The method of claim 1 , wherein the binge behavior is associated with alcohol consumption, eating, tobacco consumption, shopping, or sexual conduct.
3. The method of claim 2 , wherein said binge behavior is binge drinking.
4. The method of claim 1 , wherein the pharmaceutically acceptable salt of the compound forms a part of a composition, which further comprises a pharmaceutically acceptable carrier.
5. The method of claim 4 , wherein the composition is in a form of a free-flowing powder, a tablet, a capsule, a lozenge, a liquid, a liquid concentrate, or a syrup.
6. The method of claim 4 , wherein the composition is a unit dosage form composition.
7. The method of claim 6 , wherein an amount of the pharmaceutically acceptable salt of the compound in the unit dosage form ranges from 30 mg to 130 mg.
8. The method of claim 7 , wherein the amount of the pharmaceutically acceptable salt of the compound is 70 mg.
9. The method of claim 1 , wherein the pharmaceutically acceptable salt of the compound is administered to the subject orally.
10. The method of claim 1 , wherein the compound is the pharmaceutically acceptable salt of 5-methoxy-2-aminoindan.
11. A pharmaceutical composition comprising a pharmaceutically acceptable salt of 5-methoxy-2-aminoindan, the composition being formulated for oral administration, and being a liquid unit dosage form composition.
12. The pharmaceutical composition of claim 11 , being packaged as a single unit dose or as a plurality of single unit doses.
13. The pharmaceutical composition of claim 12 , wherein said unit dosage form comprises from 30 mg to 130 mg of the pharmaceutically acceptable salt of 5-methoxy-2-aminoindan.
Assignments (3)
CHANGE OF NAME
Recorded Oct 20, 2025
From: CLEARMIND MEDICINE INC.
To: CLEARMIND LABS CORP.
Reel/Frame 072605/0741 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jan 27, 2022
From: EZEKIAL GOLAN; DIET ALCOHOL CORPORATION OF THE AMERICAS
To: CYNTAR VENTURES, INC.
Reel/Frame 058796/0583 →
CHANGE OF NAME
Recorded Jan 27, 2022
From: CYNTAR VENTURES, INC.
To: CLEARMIND MEDICINE INC.
Reel/Frame 058797/0479 →
Continuity (6)
Continuation
15534137
Provisional Application
62089504
· Dec 9, 2014
Provisional Application
62089500
· Dec 9, 2014
References Cited (86)
US 2712998A
· Vosseler
· 1955
[cited by applicant]
US 4990350A
· Rohmann
· 1991
[cited by applicant]
US 5708018A
· Haadsma-Svensson
· 1998
[cited by examiner]
US 6933410B2
· Prashad et al.
· 2005
[cited by applicant]
US 20100113512A1
· Ignar
· 2010
[cited by applicant]
DE 952441
· 1956
[cited by applicant]
EP 2556830
· 2013
[cited by applicant]
WO WO199504713
· 1995
[cited by applicant]
WO WO199914207
· 1999
[cited by applicant]
WO WO199919325
· 1999
[cited by applicant]
WO WO200134172
· 2001
[cited by applicant]
WO WO2002064545
· 2002
[cited by applicant]
WO WO2004037777A
· 2004
[cited by applicant]
WO WO2006015828
· 2006
[cited by applicant]
WO WO2007069925
· 2007
[cited by applicant]
WO WO2008021849A2
· 2008
[cited by applicant]
WO WO2009125923
· 2009
[cited by applicant]
WO WO2016092546
· 2016
[cited by applicant]
WO WO2016092547
· 2016
[cited by applicant]
Vengeliene et al The FASEB Journal, 2006, 20, 2223-2233 (Year: 2006).
[cited by examiner]
Halberstadt et al., “2-Aminoindan and its ring-substituted derivatives interact with plasma membrane monoamine transporters and α2-adrenergic receptors”, Psychopharmacology, vol. 236, pp. 989-999, published Mar. 2019, U…
[cited by applicant]
Akbaba et al. “Synthesis and Asymmetric Resolution of A Dopaminergic Compound: 2-Amino-5-Methoxyindane”, Tetrahedron Asymmetry, XP029554246, 27(11): 475-479, Available Online Apr. 28, 2016.
[cited by applicant]
Akincioglu et al. “Novel Sulfamides as Potential Carbonic Anhydrase Isoenzymes Inhibitors”, Bioorganic & Medicinal Chemistry, 21(6): 1379-1385, Available Online Jan. 22, 2013.
[cited by applicant]
Anton et al. “Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence”, Journal of the American Medical Association, JAMA, 295(17): 2003-2017, May 3, 2006.
[cited by applicant]
Applicant-Initiated Interview Summary Dated Feb. 26, 2020 From the US Patent and Trademark Office Re. U.S. Appl. No. 15/534,121. (3 pages).
[cited by applicant]
Arneric et al. “Potent Anorexic-Like Effects of RDS-127 (2-Di-N-Propylamino-4, 7-Dimethoxyindane) in the Rat: A Comparison With Other Dopamine-Receptor Agonists”, Neuropharmacology, XP025559703, 21(9), 885-890, Sep. 1, …
[cited by applicant]
Bluelight “5-Meo-Al”, Bluelight, 6 P., Dec. 31, 2014.
[cited by applicant]
Boyce et al. “Enhancement of Ethanol Reward By Dopamine D3 Receptor Blockade”, Brnn Research, 88(1): 202-206, Aug. 2, 2000.
[cited by applicant]
Brandt et al. “Aminoindane Analogues”. Novel Psychoactive Substances, Academic Press, pp. 261-283. Jan. 1, 2013.
[cited by applicant]
Burn-Callander et al. “Get Drunk Without A Hangover on Synthetic Booze”, Telegraph Media Group, 4 P,, Jan. 22, 2015.
[cited by applicant]
Chick et al. “Substitution Therapy for Alcoholism: Time for A Reappraisal?”, Journal of Psychopharmacology, 26(2): 205-212, Published Online Jul. 8, 2011.
[cited by applicant]
Decision on Rejection Dated Mar. 26, 2020 From the National Intellectual Property Administration of the People's Republic of China Re. Application No. 201580075683.X and Its Translation Into English. (14 Pages).
[cited by applicant]
Decision on Rejection Dated Mar. 26, 2020 From the National Intellectual Property Administration of the People's Republic of China Re. Application No. 201580075683.X and Its Translation Into English. (24 Pages).
[cited by applicant]
European Search Report and the European Search Opinion Dated Aug. 12, 2020 From the European Patent Office Re. Application No. 20161755.2. (14 Pages).
[cited by applicant]
Examination Report Under Sections 12 & 13 of the Patents Act, 1970 and the Patents Rules, 2003 Dated Dec. 24, 2019 From the Government of India, Intellectual Property India, Patents, Designs, Trade Marks, Geographical I…
[cited by applicant]
Examination Report Under Sections 12 & 13 of the Patents Act, 1970 and the Patents Rules, 2003 Dated Nov. 7, 2020 From the Government of India, The Patent Office, Intellectual Property India, Patents, Designs, Trade Mar…
[cited by applicant]
Examination Report Under Sections 12 & 13 of the Patents Act, 1970 and the Patents Rules, 2003 Dated Nov. 7, 2019 From the Government of India, The Patent Office, Intellectual Property India, Patents, Designs, Trade Mar…
[cited by applicant]
Final Official Action Dated Feb. 3, 2021 From the US Patent and Trademark Office Re. U.S. Appl. No. 15/534,121. (16 Pages).
[cited by applicant]
Fisher “Doctors Have Discovered the Simplest Way to Quit Drinking—By Doing Drugs”, Mic, 2 P., Jan. 8, 2015.
[cited by applicant]
Giuliano et al. “Attenuation of Cocaine and Heroin Seeking by [mu]-opioid Receptor Antagonism”, Psychopharmacology, XP035370001, 227(1): 137-147, Published Online Jan. 9, 2013.
[cited by applicant]
Gray “Could A Legal High That Mimics Ecstasy Stop People From Boozing? Party Drug Is Patented for Use as ‘Binge Mitigation Agent’”, Daily Mail Online, 16 P., Dec. 31, 2014.
[cited by applicant]
Haadsma-Svensson et al. “Dopamine D3 Receptor Antagonists. 1. Synthesis and Structure-Activity Relationships of 5,6-Dimethoxy-N-Alkyl- and N-Alkylaryl-Substituted 2-Aminoindans”, The Journal of Medicinal Chemistry, 44(2…
[cited by applicant]
Heidbreder et al. “Role of Dopamine D3 Receptors in the Addictive Properties of Ethanol”, Drugs of Today, 40(4): 355-365, 2004.
[cited by applicant]
International Preliminary Report on Patentability Dated Jun. 22, 2017 From the International Bureau of WIPO Re. Application No. PCT/IL2015/051193. (8 Pages).
[cited by applicant]
International Preliminary Report on Patentability Dated Jun. 22, 2017 From the International Bureau of WIPO Re. Application No. PCT/IL2015/051194. (8 Pages).
[cited by applicant]
International Search Report and the Written Opinion Dated Apr. 4, 2016 From the International Searching Authority Re. Application No. PCT/IL2015/051193.
[cited by applicant]
International Search Report and the Written Opinion Dated Mar. 22, 2016 From the International Searching Authority Re. Application No. PCT/IL2015/051194.
[cited by applicant]
Johnson “Progress in the Development of Topiramate for Treating Alcohol Dependence: From A Hypthesis to A Proof-of-Concept Study”, Alcoholism: Clinical and Experimental Research, 28(8): 1137-1144, Aug. 2004.
[cited by applicant]
Karhuvaara et al. “Targeted Nalmefene With Simple Medical Management in the Treatment of Heavy Drinkers: A Randomized Double-Blind Placebo-Controlled Multicenter Study”, Alcolholism: Clinical and Experimental Research, …
[cited by applicant]
Kelly et al. “The Opioid Receptor Pharmacology of GSK1521498 Compared to Other Ligands With Differential Effects on Compulsive Reward-related Behaviours”. Psychopharmacology, XP035416399, 232(1): 305-314, Published Onli…
[cited by applicant]
Koob “Alcoholism: Allostasis and Beyond”, Alcoholism: Clinical and Experimental Research, 27(2): 232-243, Feb. 2003.
[cited by applicant]
Lingford-Hughes et al. “Neuropharmacology of Addiction and Flow It Informs Treatment”. British Medical Bulletin, 96: 93-110, Published Online Nov. 2, 2010.
[cited by applicant]
Notice Of Allowance Dated Jul. 20, 2018 From the US Patent and Trademark Office Re. U.S. Appl. No. 15/534,137. (7 pages).
[cited by applicant]
Notification of Office Action and Search Report Dated Dec. 20, 2018 From the National Intellectual Property Administration of the People's Republic of China Re. Application No. 201580075683.X and Its Summary in English.…
[cited by applicant]
Notification of Office Action and Search Report Dated Dec. 20, 2018 From the State Intellectual Property Office of the People's Republic of China Re. Application No. 201580075677.4 and Its Summary in English. (12 Pages).
[cited by applicant]
Notification of Office Action Dated Aug. 21, 2019 From the National Intellectual Property Administration of the People's Republic of China Re. Application No. 201580075677.4 and Its Translation Into English. (17 Pages).
[cited by applicant]
Notification of Office Action Dated Aug. 21, 2019 From the National Intellectual Property Administration of the People's Republic of China Re. Application No. 201580075683.X and Its Translation Into English. (15 Pages).
[cited by applicant]
Nutt “Alcohol Without the Hangover? It's Closer Than You Think”, The Guardian, 2 P., Nov. 11, 2013.
[cited by applicant]
Nutt et al. “Through A Glass Darkly: Can We Improve Clarity About Mechanism and Aims of Medications in Drug and Alcohol Treatments?”, Journal of Physchopharmacology, 26(2): 199-204, Feb. 2012.
[cited by applicant]
Official Action Dated Dec. 11, 2018 From the US Patent and Trademark Office Re. U.S. Appl. No. 16/167,576. (13 pages).
[cited by applicant]
Official Action Dated Mar. 14, 2018 From the US Patent and Trademark Office Re. U.S. Appl. No. 15/534,137. (13 pages).
[cited by applicant]
Official Action Dated May 21, 2020 from the US Patent and Trademark Office Re. U.S. Appl. No. 15/534,121. (14 pages).
[cited by applicant]
Official Action Dated Apr. 26, 2018 From the US Patent and Trademark Office Re. U.S. Appl. No. 15/534,121. (14 pages).
[cited by applicant]
Official Action Dated Feb. 27, 2019 From the US Patent and Trademark Office Re. U.S. Appl. No. 15/534,121. (24 pages).
[cited by applicant]
Official Action Dated Oct. 29, 2019 From the US Patent and Trademark Office Re. U.S. Appl. No. 15/534,121. (18 Pages).
[cited by applicant]
Restriction Official Action Dated Feb. 1, 2018 From the US Patent and Trademark Office Re. U.S. Appl. No. 15/534,121. (14 pages).
[cited by applicant]
Roesner et al. “Acamprosate Supports Abstinence, Naltrexone Prevents Excessive Drinking: Evidence From A Meta-Analysis With Unreported Outcomes”, Journal of Psychopharmacology, 22(1): 11-23, Jan. 2008.
[cited by applicant]
Shimshoni et al. “Toxicological Evaluation of 5-Methoxy-2-Aminoindane (MEAi): Binge Mitigating Agent in Development”, Toxicology and Applied Pharmacology, XP029927268, 319: 59-68, Available Online Feb. 4, 2017.
[cited by applicant]
Skett “Care for A Legal Hight That's ‘Chaperon-ed by Imperial’? New Party Drug Currently Being Developed by Nutt's Team Could Stop Binge Drinking But Still Deliver A High”, News—Felix Online, 5 P., Jan. 16, 2015.
[cited by applicant]
Slezak “High and Dry? Party Drug Could Target Excess Drinking. A Patent Has Been Filed for A Drug That Produces Some of Ecstasy's Euphoric Effects—and Seems to Put the Brakes on Boozing”, New Scientist, 5 P., Dec. 30, 2…
[cited by applicant]
Supplementary European Search Report and the European Search Opinion Dated Jul. 2, 2018 From the European Patent Office Re. Application No. 15867070.3. (11 Pages).
[cited by applicant]
Supplementary European Search Report and the European Search Opinion Dated Jul. 2, 2018 From the European Patent Office Re. Application No. 15867972.0. (8 Pages).
[cited by applicant]
Traits “How Safe Are My Drugs?”, BBC Three, 3 P., Jan. 29, 2015.
[cited by applicant]
Vengeliene et al. “The Dopamine D3 Receptor Plays An Essential Role in Alcohol-Seeking and Relapse”, The FASEB Journal, 20(13): 2223-2233, Jan. 1, 2006.
[cited by applicant]
Weiss et al. “Behavioral Neurobiology of Alcohol Addiction: Recent Advances and Challenges”, The Journal of Neuroscience, 22(9): 3332-3337, May 1, 2002.
[cited by applicant]
Wikipedia “MEAI”, Wikipedia, the Free Encyclopedia, 2 P., Last Modified Dec. 13, 2015.
[cited by applicant]
Ziauddeen et al. “Effects of the Mu-opioid Receptor Antagonist GSK1521498 on Hedonic and Consummatory Eating Behaviour: A Proof of Mechanism Study in Binge-Eating Obese Subjects”, Molecular Psychiatry, XP9506312, 18(12)…
[cited by applicant]
Shimshoni Jakob A. et al: “Pharmacokinetic and pharmacodynamic evaluation of 5-methoxy-2-aminoindane (MEAi): A new binge-mitigating agent”, Toxicology and Applied Pharmacology, vol. 343, Mar. 1, 2018, pp. 29-39, XP93072…
[cited by applicant]